Cite
Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study.
MLA
Garcia, Betzabel N.Cajiao, et al. “Prevalence of KRAS p.(G12C) in Stage IV NSCLC Patients in the Netherlands; a Nation-Wide Retrospective Cohort Study.” Lung Cancer (Amsterdam, Netherlands), vol. 167, May 2022, pp. 1–7. EBSCOhost, https://doi.org/10.1016/j.lungcan.2022.03.015.
APA
Garcia, B. N. C., van Kempen, L. C., Kuijpers, C. C. H. J., Schuuring, E., Willems, S. M., & van der Wekken, A. J. (2022). Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study. Lung Cancer (Amsterdam, Netherlands), 167, 1–7. https://doi.org/10.1016/j.lungcan.2022.03.015
Chicago
Garcia, Betzabel N Cajiao, Léon C van Kempen, Chantal C H J Kuijpers, Ed Schuuring, Stefan M Willems, and Anthonie J van der Wekken. 2022. “Prevalence of KRAS p.(G12C) in Stage IV NSCLC Patients in the Netherlands; a Nation-Wide Retrospective Cohort Study.” Lung Cancer (Amsterdam, Netherlands) 167 (May): 1–7. doi:10.1016/j.lungcan.2022.03.015.